Conclusions
We have shown that a novel, BID FDC of aclidinium and formoterol, administered over six months, significantly improves endpoints that are important to patients with COPD, namely, symptoms (TDI; daily, night-time and early-morning symptoms), relief-medication use and both reported and unreported exacerbations (moderate or severe exacerbations measured by HCRU and exacerbations of any severity measured by EXACT). Improvements in lung function with the FDC versus monotherapy were expected, in line with other recent combination data. However, pooling data from two studies of near-identical design has allowed a more comprehensive investigation of the benefits of the FDC in terms of symptoms and exacerbations. The results are consistent with the improvements in bronchodilation observed in the individual studies and confirm that aclidinium/formoterol FDC 400/12 μg BID may be an effective new treatment option for patients with moderate to severe COPD.
Endnotes
Registered trademark of AstraZeneca group of companies; for use within the USA as Pressair® and as Genuair™ within all other licensed territories.